Ignite Creation Date:
2024-05-06 @ 12:27 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03768531
Status:
WITHDRAWN
Last Update Posted:
2020-04-13
First Post:
2018-12-05
Brief Title:
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization Data
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Class:
OTHER
Study ID:
J18162
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |